Factor VII Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Factor VII deficiency is the commonest of the ‘rare inherited bleeding disorders characterized by a deficiency or reduced activity of clotting factor VII. It is the complex formed by activated factor VII and tissue factor (TF), which plays a leading role in initiating the extrinsic arm of the coagulation cascade. Individuals with factor VII deficiency can experience prolonged, uncontrolled bleeding episodes. The symptoms and severity of factor VII deficiency are highly variable; no consistent correlation between the amount of factor VII in the blood and overall severity is seen. Some individuals may not develop any symptoms (asymptomatic), including individuals with relatively low levels of factor VII.
·
The incidence cases of Factor VII deficiency
ranges between 1.5 to 2.75 cases per 150,000 to 250,000 individuals in the USA.
Thelansis’s “Factor VII Deficiency
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Factor
VII Deficiency treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Factor VII Deficiency across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Factor VII Deficiency Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment